Rel­ma­da makes 'crit­i­cal changes' to PhI­II tri­al to try and save de­pres­sion drug

Rel­ma­da Ther­a­peu­tics is mak­ing changes to its Phase III study of its lead drug for ma­jor de­pres­sive dis­or­der, in an at­tempt to avoid prob­lems with a pri­or tri­al that showed lit­tle dif­fer­ence be­tween the drug and a place­bo.

That fail­ure in Oc­to­ber wiped 80% from Rel­ma­da’s stock price, and was fol­lowed by an­oth­er neg­a­tive read­out a few months lat­er. In both cas­es, the com­pa­ny said that there had been tri­al sites that were as­so­ci­at­ed with what it called sur­pris­ing place­bo ef­fects that skewed the re­sults com­pared with the drug, REL-1017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER